News

You are here

Chronic Obstructive Pulmonary Disease (COPD) is a significant healthcare problem, with an estimated 384 million cases worldwide in 2010.1 Population aging is predicted to drive further growth, with one study forecasting a 150% increase in prevalence overall, and up to 220% in the 75 and over age group, between 2010 and 2030.2

Air pollution is a key asthma trigger affecting thousands of Canadians every year. It can be visible or invisible and comes from many different sources including:

Treatment with the Aerobika* device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits, according to a study published this month in Pulmonary Therapy.1 The study also showed that per-patient cost of exacerbations was significantly lower in the Aerobika* device group. This study provides the first real-world evidence for the benefits of using the Aerobika* device in reducing exacerbation-related emergency department visits and hospital readmissions.

Pages